

Title (en)

METHODS AND COMPOSITIONS FOR PREDICTING, DIAGNOSING AND TREATING LIPODYSTROPHY

Title (de)

VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BESTIMMUNG, DIAGNOSE UND BEHANDLUNG VON LIPODYSTROPHY

Title (fr)

PROCEDES ET COMPOSITIONS POUR PREVOIR, DIAGNOSTIQUER ET TRAITER LA LIPODYSTROPHIE

Publication

**EP 1223983 A2 20020724 (EN)**

Application

**EP 00969122 A 20001018**

Priority

- CA 0001208 W 20001018
- CA 2289365 A 19991112
- US 16034699 P 19991019

Abstract (en)

[origin: WO0128532A2] This invention relates to a method of predicting those individuals at risk of developing lipodystrophy associated with antiretroviral therapy is disclosed. The method includes the steps of: (a) measuring CD36 levels in the patient prior to protease inhibitor or antiretroviral therapy; (b) measuring CD36 levels in the patient after initiating protease inhibitor or antiretroviral therapy; (c) determining whether CD36 levels after antiretroviral or protease inhibitor therapy are changed after therapy, a change in CD36 levels being predictive of the subsequent development of lipodystrophy. The invention also includes a composition for treating or preventing lipodystrophy associated with PI or antiretroviral therapy. The composition includes PPAR gamma -RXR agonist to up-regulate CD36 in admixture with a pharmaceutically acceptable carrier, excipient, or diluent. The composition can be used in a method to prevent or treat lipodystrophy. The invention also includes a method of determining whether a test compound causes lipodystrophy in a mammal.

IPC 1-7

**A61K 45/00**; **A61K 45/06**; **A61P 3/06**

IPC 8 full level

**A61K 31/00** (2006.01); **A61K 31/07** (2006.01); **A61K 31/192** (2006.01); **A61K 31/196** (2006.01); **A61K 31/201** (2006.01); **A61K 31/203** (2006.01); **A61K 31/405** (2006.01); **A61K 31/427** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/472** (2006.01); **A61K 31/496** (2006.01); **A61K 31/513** (2006.01); **A61K 31/557** (2006.01); **A61K 38/17** (2006.01); **A61K 38/19** (2006.01); **A61K 38/20** (2006.01); **G01N 33/569** (2006.01)

CPC (source: EP)

**A61K 31/00** (2013.01); **A61K 31/07** (2013.01); **A61K 31/192** (2013.01); **A61K 31/196** (2013.01); **A61K 31/201** (2013.01); **A61K 31/203** (2013.01); **A61K 31/405** (2013.01); **A61K 31/427** (2013.01); **A61K 31/4439** (2013.01); **A61K 31/472** (2013.01); **A61K 31/473** (2013.01); **A61K 31/496** (2013.01); **A61K 31/513** (2013.01); **A61K 31/557** (2013.01); **A61K 31/5575** (2013.01); **A61K 38/1709** (2013.01); **A61K 38/193** (2013.01); **A61K 38/2026** (2013.01); **A61P 3/06** (2017.12); **G01N 33/56988** (2013.01); **G01N 2333/70596** (2013.01); **G01N 2500/00** (2013.01)

Citation (search report)

See references of WO 0128532A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

**WO 0128532 A2 20010426**; **WO 0128532 A3 20020103**; AU 7894900 A 20010430; EP 1223983 A2 20020724

DOCDB simple family (application)

**CA 0001208 W 20001018**; AU 7894900 A 20001018; EP 00969122 A 20001018